The #AIEye
#Podcast:
GBT Technologies’ (OTC PINK: $GTCH) qTerm Adds #AI to Human Vital Signs Device; CTO
Discusses New AI #MedicalTechnology
Point Roberts WA, Vancouver BC –
April 8, 2020 – Investorideas.com (www.investorideas.com), a global investor news source
covering Artificial Intelligence (AI) brings you a
special edition of the The AI Eye, looking at advancements in
artificial intelligence, featuring an exclusive interview with GBT Technologies
Inc. (OTC PINK:GTCH) discussing the conception , design
and development of its new AI medical technology.
Listen to today’s podcast:
Read this in full
at https://www.investorideas.com/news/2020/artificial-intelligence/04081AIEye-GTCH-qTerm.asp
GBT Technologies Inc.'s (OTC PINK:GTCH) intelligent human vital signs device qTerm is distinguished by
its AI-powered features, according to company CTO, Danny Rittman.
qTerm measures a user’s vital signs
and reports them to the user. The device is the result of a joint venture
between GBT and Tokenize-It, S.A., called GBT Tokenize Corp. A recent press release announced that development of the
device has begun.
The device, according to Rittman is,
“Conceptually, as it is in design stage, is a combination of hardware and embedded
software, making it capable of taking, on the fly and in a matter of seconds,
body temperature, heart rate, and blood pressure. And in the future we’ll
probably add blood-oxygen level,” he said. But what separates qTerm from similar devices is its inclusion
of AI.
“It’s going to incorporate not just
the electronics of the measuring sensors, but an artificial intelligence unit
that is going to collect the data and basically keep it per customer, per user
– of course with the user’s permission – [and] save it in a central,
secure database,” Rittman said. “It’s not just another measuring device, it’s
an intelligent device that’s going to incorporate a whole database per user per
human body vitals.”
This capability yields a “thermal map” that identifies “HOT
SPOTS” – areas of users with higher-than-normal temperatures – which users
can then avoid so as to reduce risk of illness. Think of it as “WAZE of the
MEDICAL MAP” – based on user in the area it can indicate a potential problem.
“Upon, of course, the user’s
permission, and without recording names or privacy invasion … the device will
record the user’s geographical spot with [their] temperature,” he said. “That
means that a higher temperature than normal is recorded [and] it will accumulate in a broad map…”
Also indicated in the press release,
is that the company intends to create both a mobile and standalone version of
the device. Highlighting its planned intuitive and user-friendly nature,
Rittman said the mobile version:
“…looks like a little button and
sticks to the back of your cell phone. It has a little touch button, you touch
it and hold your finger there between five and ten seconds, and in this time it
is activated, takes your body vitals (temperature, heart rate, blood pressure), transmits it to
your phone via Bluetooth device and you can see the results on your phone.”
The development of qTerm also reflects some of the major
trends observed in telemedicine – the remote diagnosis and treatment of
patients by means of telecommunications technology. An article from the site Medical Alert Advice notes the tendency in the space
toward better mobile tech and apps to further proliferate access to healthcare.
While not an app, qTerm’s mobility lends itself to this trend in its mobility.
In a sense, telemedicine is following the
trend of all technological advancements of recent years -providing a service
that patients can access in the palm of their hands.
One of the key elements in making
telemedicine technologies work is greater access to information and data. This
trend can be observed in qTerm, given the ease with which it can
measure and record such data (“touch it and hold your finger there
between five and ten seconds”).
qTerm’s development is also notable
for its potential concurrence with the COVID-19 pandemic. IBM (NYSE:IBM), a veteran in the field, recently announced that it is making its AI-powered “Watson Assistant for Citizens”
freely available for 90 days in an effort to spread information and awareness
about the virus. For its part, Watson Assistant for Citizens leverages AI
search capabilities to advance critical information to citizens.
With restrictions on businesses and social gatherings
increasing as governments scramble to slow the spread of COVID-19, a product like qTerm could be
potentially in the future invaluable
with its application in identifying high risk areas.
“We believe that this type of
product can really assist, especially in the world health crisis that’s going
on,” Rittman said. “Giving and providing hotspots worldwide can help fight this
pandemic.”
Interview by Sam Mowers,
Investorideas.com
For a list of artificial intelligence stocks on
Investorideas.com visit here or
become an Investor Ideas member
About
Investorideas.com - News that Inspires Big
Investing Ideas Investorideas.com is a recognized news source publishing
third party news, research and original financial content. Learn about
investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis,
crypto, AI and IoT, mining, sports biotech, water, renewable energy and more.
Investor Idea’s original branded content includes the following podcasts and
columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the
Move podcast and column, Cleantech and Climate
Change , Exploring Mining
the AI Eye .
The Investorideas.com podcasts are also available on
iTunes, Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio and Google Play Music.
Visit the Podcast page at Investorideas.com:
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: GBT Technologies is a paid monthly client for news and social media on
Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com
newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to
regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
The
AI Eye- Watching stock news, deal tracker and
advancements in artificial intelligence is an original content brand of
Investorideas.com
Contact
Investorideas.com
800 665 0411
